Cumberland Pharmaceuticals CPIX Payment for Contingent Consideration Liability, Financing Activities
Payment for Contingent Consideration Liability, Financing Activities at other companies
Other financials
Where this comes from
Reported directly by Cumberland Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities.
The official record: Cumberland Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cumberland Pharmaceuticals's payment for contingent consideration liability, financing activities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cumberland Pharmaceuticals's payment for contingent consideration liability, financing activities?
- Cumberland Pharmaceuticals (CPIX) reported payment for contingent consideration liability, financing activities of $702.3K in Q1 2026.
- How has Cumberland Pharmaceuticals's payment for contingent consideration liability, financing activities changed year-over-year?
- Cumberland Pharmaceuticals's payment for contingent consideration liability, financing activities increased by 37.4% year-over-year, from $511.13K to $702.3K.
- What is the long-term trend for Cumberland Pharmaceuticals's payment for contingent consideration liability, financing activities?
- Over 4 years (2021 to 2025), Cumberland Pharmaceuticals's payment for contingent consideration liability, financing activities has grown at a -5.7% compound annual growth rate (CAGR), from $2.17M to $1.71M.